OBJECTIVE: To determine whether recent use of topical fluoroquinolones is a risk factor for in vitro fluoroquinolone resistance in Staphylococcus aureus ocular isolates. METHODS: Disk diffusion susceptibility testing for ciprofloxacin, moxifloxacin, and gatifloxacin was performed for all ocular isolates of S aureus at the Francis I. Proctor Foundation microbiology laboratory from January 1, 2005, to December 31, 2008. The medical records of patients with positive S aureus cultures were reviewed to determine topical or systemic fluoroquinolone use within the 3 months prior to culture. The Fisher exact test was used to compare the proportion of patients who used topical fluoroquinolones in the past 3 months among fluoroquinolone-sensitive and -resistant cases. Logistic regression was used to determine risk factors for fluoroquinolone resistance. RESULTS: Of 200 S aureus cultures, 41 were resistant to ciprofloxacin, moxifloxacin, and gatifloxacin (20.5%). Fluoroquinolone-resistant S aureus isolates were from older patients (mean [SD] age, 65.5 [25.0] years) compared with fluoroquinolone-susceptible isolates (mean [SD] patient age, 52.1 [22.1] years) (P = .003). Use of fluoroquinolones within the 3 months before testing was more frequent in resistant isolates (29%) than in susceptible isolates (11%) (P = .005), as was recent hospitalization (22% of resistant isolates, 0% of susceptible isolates) (P < .001). In the multivariate regression analysis, topical fluoroquinolone use within 3 months was a significant predictor of fluoroquinolone resistance (P = .046), along with age, systemic immunosuppression, and topical fluoroquinolone use between 3 and 6 months before testing. CONCLUSION: Recent topical fluoroquinolone use is significantly associated with fluoroquinolone resistance in S aureus isolates from ocular cultures.
OBJECTIVE: To determine whether recent use of topical fluoroquinolones is a risk factor for in vitro fluoroquinolone resistance in Staphylococcus aureus ocular isolates. METHODS: Disk diffusion susceptibility testing for ciprofloxacin, moxifloxacin, and gatifloxacin was performed for all ocular isolates of S aureus at the Francis I. Proctor Foundation microbiology laboratory from January 1, 2005, to December 31, 2008. The medical records of patients with positive S aureus cultures were reviewed to determine topical or systemic fluoroquinolone use within the 3 months prior to culture. The Fisher exact test was used to compare the proportion of patients who used topical fluoroquinolones in the past 3 months among fluoroquinolone-sensitive and -resistant cases. Logistic regression was used to determine risk factors for fluoroquinolone resistance. RESULTS: Of 200 S aureus cultures, 41 were resistant to ciprofloxacin, moxifloxacin, and gatifloxacin (20.5%). Fluoroquinolone-resistant S aureus isolates were from older patients (mean [SD] age, 65.5 [25.0] years) compared with fluoroquinolone-susceptible isolates (mean [SD] patient age, 52.1 [22.1] years) (P = .003). Use of fluoroquinolones within the 3 months before testing was more frequent in resistant isolates (29%) than in susceptible isolates (11%) (P = .005), as was recent hospitalization (22% of resistant isolates, 0% of susceptible isolates) (P < .001). In the multivariate regression analysis, topical fluoroquinolone use within 3 months was a significant predictor of fluoroquinolone resistance (P = .046), along with age, systemic immunosuppression, and topical fluoroquinolone use between 3 and 6 months before testing. CONCLUSION: Recent topical fluoroquinolone use is significantly associated with fluoroquinolone resistance in S aureus isolates from ocular cultures.
Authors: B D Gaynor; J D Chidambaram; V Cevallos; Y Miao; K Miller; H C Jha; R C Bhatta; J S P Chaudhary; S Osaki Holm; J P Whitcher; K A Holbrook; A M Fry; T M Lietman Journal: Br J Ophthalmol Date: 2005-09 Impact factor: 4.638
Authors: H Seppälä; T Klaukka; J Vuopio-Varkila; A Muotiala; H Helenius; K Lager; P Huovinen Journal: N Engl J Med Date: 1997-08-14 Impact factor: 91.245
Authors: Ebbing Lautenbach; Neil O Fishman; Warren B Bilker; Analia Castiglioni; Joshua P Metlay; Paul H Edelstein; Brian L Strom Journal: Arch Intern Med Date: 2002-11-25
Authors: Vilhjalmur A Arason; Johann A Sigurdsson; Helga Erlendsdottir; Sigurdur Gudmundsson; Karl G Kristinsson Journal: Microb Drug Resist Date: 2006 Impact factor: 3.431
Authors: Galia Barkai; David Greenberg; Noga Givon-Lavi; Eli Dreifuss; Daniel Vardy; Ron Dagan Journal: Emerg Infect Dis Date: 2005-06 Impact factor: 6.883
Authors: George A O'Toole; Michel Wathier; Michael E Zegans; Robert M Q Shanks; Regis Kowalski; Mark W Grinstaff Journal: Cornea Date: 2012-07 Impact factor: 2.651
Authors: Catherine E Oldenburg; Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Durga S Borkar; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya Journal: Ophthalmic Epidemiol Date: 2013-05-10 Impact factor: 1.648